Condition
GPC3 Positive Hepatocellular Carcinoma
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (2)
Trial Status
Recruiting2
Withdrawn1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07493044Phase 1Recruiting
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
NCT07242417Early Phase 1Recruiting
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
NCT02723942Phase 1WithdrawnPrimary
CAR-T Cell Immunotherapy for HCC Targeting GPC3
Showing all 3 trials